Aptinyx Inc

Aptinyx Inc. is a clinical stage biopharmaceutical company, which engages in discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. This mechanism has applicability across a number of CNS disorders. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need.

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the Company will be participating in two upcoming conferences: 4th Annual Neuroscience Innovation Forum – Norbert Riedel, Ph.D., chief executive officer, will participate in the Pain & Addiction Panel discussion at 11:30 a.m. ET on April 29, 2021; and 7th Annual Truist Securi

Aptinyx to Participate in Upcoming Conferences

Bioline RX

Cyclerion Therapeutics Inc

Lineage Cell Therapeutics Inc

Palatin Technologies

5 Penny Stocks To Watch For The Last Week Of April 2021 The post Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week

The stock price of Aptinyx (NASDAQ: APTX) increased by over 4% pre-market. This is why it happened.

Aptinyx Stock Price Increased Over 4% Pre-Market: Why It Happened

Aptinyx Inc (NASDAQ: APTX) has restarted patient screening in a Phase 2 study evaluating NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinson's disease and dementia with Lewy bodies. Aptinyx will release the data from this study in the second half of 2022.

Aptinyx Stock Is Trading Higher After Restarting NYX-458 Study In Dementia Associated Cognitive Impairment

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has recommenced patient screening in a Phase 2 study of NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinson's disease and dementia with Lewy bodies. The company anticipates reporting data from this study in the second half of 2022. “W

Aptinyx Recommences Phase 2 Study of NYX-458 in Patients with Cognitive Impairment Associated with Parkinson's Disease Dementia and Dementia with Lewy Bodies

Aptinyx Inc. (APTX) CEO Norbert Riedel on Q4 2020 Results - Earnings Call Transcript

Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 16.67% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Aptinyx Inc. (APTX) Reports Q4 Loss, Lags Revenue Estimates

Shares of Aptinyx (NASDAQ:APTX) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 51.22% year over year to ($0.20), which beat the estimate of ($0.24).

Aptinyx: Q4 Earnings Insights

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the fourth quarter and full year 2020 and provided updates across the company's pipeline of novel NMDA receptor modulators. “Despite the COVID-19 pandemic, we are excited to be advancing clinical development across all four of our pipeline programs,” said Norbert

Aptinyx Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aptinyx Inc. (APTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Wednesday, March 24, 2021 at 5:00 p.m. ET to report fourth quarter and full year 2020 financial results and discuss recent business highlights. To access the live conference call, please dial (833) 772-0394 (domestic) or

Aptinyx to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, March 24, 2021

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in a virtual fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 10:40 a.m. EST. A live webcast of the presentation will be available to view on the “Events and Presentations” page in the

Aptinyx to Participate at 10th Annual SVB Leerink Global Healthcare Conference

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the publication of a recent review article in Medicine in Drug Discovery featuring data on its novel NMDA receptor modulator, NYX-2925. The data span across numerous preclinical models and highlight the potential therapeutic benefits of NYX-2925 in treating chronic, centralized pain c

Aptinyx Announces Publication of Review Article Highlighting Preclinical Data in Medicine in Drug Discovery Demonstrating the Potential of NYX-2925 to Treat Chronic, Centralized Pain Conditions

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in the H.C. Wainwright BioConnect 2021 Conference to be held virtually January 11-14, 2021. The fireside chat will be available on-demand through the H.C. Wainwright conference portal, beginning at 6:00 AM ET on Monday, January 11, 2021. A webc

Aptinyx to Participate in H.C. Wainwright BioConnect 2021 Conference

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that in December it recommenced patient recruitment and screening in a Phase 2 study of NYX-2925 in patients with painful diabetic peripheral neuropathy (DPN). Enrollment in the study had been suspended due to the escalation of the COVID-19 pandemic in the United States. “We are pleas

Aptinyx Announces Recommencement of Phase 2 Study of NYX-2925 in Patients With Painful Diabetic Peripheral Neuropathy

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will present virtually at the 39th Annual J.P. Morgan Healthcare Conference. Norbert Riedel, Ph.D., chief executive officer, is scheduled to present on Thursday, January 14, 2021 at 9:10 a.m. Eastern Time. A live webcast of the presentation will be available to view o

Aptinyx to Present at the 39th Annual J.P. Morgan Healthcare Conference

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the appointment of Andy Kidd, the company's current chief operating officer, to the role of president and chief operating officer, effective December 14, 2020. “We are thrilled to have Andy expand his role as president and chief operating officer, given his strong commitment to our co

Aptinyx Appoints Andy Kidd, M.D., President and Chief Operating Officer

Aptinyx Inc (APTX) CEO Norbert Riedel on Q3 2020 Results - Earnings Call Transcript

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2020 and highlighted recent progress across the company's clinical-stage pipeline of novel NMDA receptor modulators. “I am very pleased with the remarkable progress we have made over the past several months despite the negative impact of COVID

Aptinyx Reports Third Quarter 2020 Financial Results and Recent Highlights

EVANSTON, Ill.--(BUSINESS WIRE)--EVANSTON, Ill., November 10, 2020 – Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management is scheduled to participate in two upcoming investor conferences: A presentation during the Stifel 2020 Virtual Healthcare Conference at 1:20 p.m. ET on Tuesday, November 17, 2020; and A pre-recorded fireside chat during the

Aptinyx to Participate in Upcoming Virtual Investor Conferences

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, November 12, 2020 at 5:00 p.m. ET to report third quarter 2020 financial results and discuss recent business highlights. To access the live conference call, please dial (833) 772-0394 (domestic) or (236) 738-22

Aptinyx to Report Third Quarter Financial Results on Thursday, November 12, 2020

The market's skepticism around Aptinyx Inc's (NASDAQ: APTX) post-traumatic stress disorder (PTSD) candidate appears overdone, according to Piper Sandler. The Aptinyx Analyst: Christopher Raymond initiated coverage of Aptinyx with an Overweight rating and a price target of $10.

Piper Sandler Initiates Coverage On Aptinyx On PTSD Candidate

Selecta Biosciences

VBI Vaccines

"Buy low, sell high" is easy when stocks are cheap. The hard part is finding inexpensive healthcare stocks that are more than just speculative trades.

3 Top Healthcare Stocks Under $5

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the closing of its public offering of 16,100,000 shares of its common stock, which included the exercise in full of the underwriters' option to purchase additional shares, at a public offering price of $3.00 per share. All of the shares sold in the offering were sold by Aptinyx. The g

Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option

Investors reacted negatively to the company's announcement of a secondary stock offering.

News for Aptinyx Inc Stock (APTX)